Establishment of Ectopic Xenografts Derived from Human Glioblastoma in Immunocompetent Mouse Model Treated with Pesticide.

Background: In this study, we suggested an experimental procedure demonstrating the impact of pesticide on the development of ectopic xenografts of human glioblastomas in immuno-competent Balb/c mice. Method: In this in-vivo study, the mice were treated with or without a mixture of pesticide (Glypho...

Full description

Bibliographic Details
Published in:Middle East Journal of Cancer Vol. 13; no. 3; pp. 384 - 393
Main Authors: Ghidouche, Abderrezak, Tliba, Souhil, Ait-Ali, Djida
Format: diagnostic images pictorial research tables/charts Journal Article
Published: Middle East Journal of Cancer Jul2022
Online Access:View this record in EBSCOhost
Description
Summary:Background: In this study, we suggested an experimental procedure demonstrating the impact of pesticide on the development of ectopic xenografts of human glioblastomas in immuno-competent Balb/c mice. Method: In this in-vivo study, the mice were treated with or without a mixture of pesticide (Glyphosate and Chlorpyrifos), using a concentration corresponding to 1/8 of LD50 of each pesticide. The pesticides were injected intraperitoneally every 72 hours. The human glioblastoma cell suspension was cultured with tumor cerebrospinal fluid and then injected subcutaneously into the treated and not treated mice with a mixture of pesticide (Glyphosate and Chlorpyrifos) following 18 days after the beginning of the experiment. Results: The body mass index of the male and female mice treated with pesticide was statistically (P = 0.0048) higher than those not treated with pesticides. 66.6% of the mice treated with pesticides and xenografts of glioblastoma developed masses at the injection site. The histological analysis revealed that 41.66% of the masses were astrocytic tumors. The other found masses corresponded to inflammatory lymph nodes and fibroblastic tissue formations. Conclusion: The treatment of mice with pesticide mixture was found to allow the development of glioblastoma xenografts in immunocompetent mice.